Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 1, 2003, Pages 56-65

  Buchacz, Kate ^a,f   Rogol, Alan D ^b   Lindsey, Jane C ^a   Wilson, Craig M ^c   Hughes, Michael D ^a   Seage III, George R ^a   Oleske, James M ^d   Rogers, Audrey Smith ^e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Insmed Incorporated   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adolescents; Adrenarche; Children; HIV; Perinatal; Puberty

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR;

ADOLESCENT; ADRENARCHE; ADULT; ARTICLE; CHILD; CHILD DEVELOPMENT; COHORT ANALYSIS; DELAYED PUBERTY; DISEASE SEVERITY; ETHNOLOGY; FEMALE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENARCHE; MULTIVARIATE ANALYSIS; PERINATAL INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEXUAL MATURATION; UNITED STATES;

EID: 0038710961     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200305010-00009     Document Type: Article

References (46)

1. Gortmaker SL, Hughes M, Cervia J, et al. for the Pediatric AIDS Clinical Trials Group Protocol 219. The impact of protease inhibitor combination therapy on mortality among children and youth infected with HIV-1. N Engl J Med 2001;345:1522-1528.
2. Hirschfeld S. Dysregulation of growth and development in HIVinfected children. J Nutr 1996;126(suppl):2641S-2650S.
3. Gertner JM, Kaufman FR, Donfield SM, et al. Delayed somatic growth and pubertal development in human immunodeficiency virus-infected hemophiliac boys: Hemophilia Growth and Development Study. J Pediatr 1994;124:896-902.
4. Moye J, Rich KC, Kalish LA, et al. for Women and Infants Transmission Study Group. Natural history of somatic growth in infants born to women infected with human immunodeficiency virus. J Pediatr 1996;128:58-69.
5. Buchacz K, Cervia JS, Lindsey JC, et al. for the Pediatric AIDS Clinical Trials Group (PACTG) 219 Study Team. Impact of protease inhibitor (PI) containing combination antiretroviral therapies on height and weight growth in HIV-infected children. Pediatrics 2001;108:E72. http://www.pediatrics.org/cgi/content/full/108/4/e72.
6. The European Collaborative Study. Weight, height and human immunodeficiency virus infection of young children of infected mothers. Pediatr Infect Dis J 1995;14:685-690.
7. McKinney RE, Robertson WR, and the Duke Pediatric AIDS Clinical Trials Unit. Effect of human immunodeficiency virus infection on growth of young children. J Pediatr 1993;123:579-582.
8. Hilgartner MW, Donfield SM, Willoughby A, et al. Hemophilia growth and development study. Design, methods, and entry data. Am J Pediatr Hematol Oncol 1993;15:208-218.
9. Kaufman FR, Gertner JM, Sleeper LA, et al. and the Hemophilia Growth and Development Study. Growth hormone secretion in HIV-positive versus HIV-negative hemophilic males with abnormal growth and pubertal development. J Acquir Immune Defic Syndr 1997;15:137-144.
10. Mahoney EM, Donfield SM, Howard C, et al. and the Hemophilia Growth and Development Study. HIV-associated immune dysfunction and delayed pubertal development in a cohort of young hemophiliacs. J Acquir Immune Defic Syndr 1999;21:333-337.
11. de Martino M, Tovo PA, Galli L, et al. for the Italian Register for HIV Infection in Children. Puberty in perinatal HIV-infection: a multicentre longitudinal study of 212 children. AIDS 2001;15: 1527-1534.
12. Biro FM, McMahon RP, Striegel-Moore R, et al. Impact of timing of pubertal maturation on growth in black and white female adolescents: The National Heart, Lung and Blood Institute Growth and Health Study. J Pediatr 2001;138:636-643.
13. Rogol AD. Early menarche and adult height: reprise of the hare and the tortoise? J Pediatr 2001;138:617-618.
14. National Center for Health Statistics. Plan and Operation of the Third National Health and Nutrition Examination Survey (1988-94). Document PHS 94-1308, Series 1. No 32. Hyattsville, MD: 1994.
15. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170-179.
16. Marshall WA, Tanner JM. Puberty. In Falkner F, Tanner JM. Human growth: a comprehensive treatise, 2nd ed. New York: Plenum Press, 1986:171-209.
17. Silver HK, Kempe CH, Bruyn HB, et al. In Handbook of pediatrics: chapter 11, adolescence, 15th ed. Los Altos: Appleton & Lange, 1984:230-245.
18. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency syndrome in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994;43:1-10.
19. Dankner WM, Lindsey JC, Levin MJ, and the Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138, 152, 179, 190, 220, 240, 245, 254, 300 and 327. Correlates of opportunistic infections in children infected with human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J 2001;20:40-48.
20. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Advance data from vital and health statistics; no. 314. Hyattsville: National Center for Health Statistics, 2000:1-27.
21. Turnbull BW. The empirical distribution function with arbitrarily grouped, censored and truncated data. J R Stat Soc Ser B 1976;38: 290-295.
22. Diggle PJ, Liang K-Y, Zeger SL. The analysis of longitudinal data New York: Oxford University Press, 1994.
23. National Center for Health Statistics. Analytic and reporting guidelines: the Third National Health and Nutrition Examination Survey, NHANES 111 (1988-94). Hyattsville, MD: Centers for Disease Control, 1996.
24. Preece MA. Prepubertal and pubertal endocrinology. In Falkner F, Tanner JM. Human growth: a comprehensive treatise, 2nd ed. New York: Plenum Press, 1986:211-224.
25. Neinstein LS, Kaufman FR. Chapter 1: normal physical growth and development. In Neinstein LS. Adolescent health care. A practical guide, 3rd ed. Baltimore: Williams & Wilkins, 1996:3-39.
26. Zhang J, Peddada SD, Malina RM, et al. Longitudinal assessment of hormonal and physical alteration during normal puberty in boys. VI Modeling of growth velocity, mean growth hormone (GH mean), and serum testosterone (T) concentrations. Am J Hum Biol 2000;12:814-824.
27. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS registry. JAMA 2000;284:190-197.
28. Nachman SA, Stanley K, Yogev R, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA 2000;283:492-498.
29. Wiznia A, Stanley K, Krogstad P, et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial-PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. AIDS Res Hum Retroviruses 2000;16:1113-1121.
30. Dreimane D, Nielsen K, Deveikis A, et al. Effect of protease inhibitors combined with standard antiretroviral therapy on linear growth and weight gain in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 2001;20:315-316.
31. Nachman S, Lindsey JC, Dankner W, et al. Lack of improvement in growth in HIV-infected children on HAART [abstract 0120]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999.
32. Miller TL, Mawn BE, Orav EJ, et al. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type-1 infected children. Pediatrics 2001;107: E77. http://www/pediatrics/org/cgi/content/full/107/5/e77.
33. Ahdieh L, Gange SJ, Greenblatt R, et al. Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am J Epidemiol 2000; 152:923-933.
34. Hilgartner MW, Donfield SM, Lynn HS, et al. and the Hemophilia Growth and Development Study. The effect of plasma human immunodeficiency virus RNA and CD4+ T lymphocytes on growth measurements in hemophilic boys and adolescents. Pediatrics 2001;107:E56. http://www.pediatrics.org/cgi/content/full/107/4/e56.
35. Morrison JA, Barton B, Biro FM, et al. Sexual maturation and obesity in 9- and 10-year-old black and white girls: the National Heart, Lung, and Blood Institute Growth and Health Study. J Pediatr 1994;124:889-895.
36. Herman-Giddens ME, Slora EJ, Wasserman RC, et al, Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings Network. Pediatrics 1997;99:505-512.
37. Harlan WR, Harlan EA, Grillo GP. Secondary sex characteristics of girls 12 to 17 years of age. The US Health Examination Survey. J Pediatr 1997;96:1074-1078.
38. Harlan WR, Grillo GP, Cornoni-Huntley J, et al. Secondary sex characteristics of boys 12 to 17 years of age. The US Health Examination Survey. J Pediatr 1979;95:293-297.
39. Freedman DS, Kettel-Khan L, Srinivasan SR, et al. Black/white differences in relative weight and obesity among girls: the Bogalusa Heart Study. Prev Med 2000;30:234-243.
40. Herman-Giddens ME, Wang L, Koch G. Secondary sexual characteristics in boys. Estimates from the National Health and Nutrition Examination Survey III, 1988-1994. Arch Pediatr Adolesc Med 2001;155:1022-1028.
41. Reiter EO, Lee PA. Have the onset and tempo of puberty changed? Arch Pediatr Adolesc Med 2001;155:988-999.
42. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in girls. Arch Dis Child 1969;44:291-303.
43. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13-23.
44. Neinstein LS, Kaufman FR. Chapter 8: abnormal physical growth and development. In Neinstein LS. Adolescent health care. A practical guide, 3rd ed. Baltimore: Williams & Wilkins, 1996:165-193.
45. Mulligan K, Grunfeld C, Hellerstein MK, et al. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993;77:956-962.
46. Werber LE, Troendle JF, Yanovski JA, et al. Effect of growth hormone treatment on testicular function, puberty, and adrenarche in boys with non-growth deficient short stature: a randomized, doubleblind placebo-controlled trial. J Pediatr 2001;138:406-410.